34th BioCity Symposium: Transforming drug development for tomorrow

The 34th BioCity Symposium focuses on drug development across a range of disease groups and on various drug modalities. Despite of significant breakthroughs in medicine, there are still numerous conditions for which there are no curative treatments, or even therapies that would effectively slow down the disease progression. Therefore, novel drug targets need to be identified and new drugs need to be discovered to target the disease-driving mechanisms. In this symposium, we will focus on academic drug discovery and on mechanisms how the promising new compounds identified in  academic setting can be converted to commercially viable industrial drug development programs. The symposium will also cover exciting new approaches to the most suitable patient populations for the emerging therapies.




Confirmed speakers

Carmen Galan, University of Bristol, UK
Christian Heinis, École Polytechnique Fédérale de Lausanne, Switzerland
David Leppert, University Hospital Basel; GeNeuro SA, Switzerland
Richard Marais, Oncodrug Ltd, UK
Francesca E. Morreale, The Francis Crick Institute, UK
Hélder A. Santos, University of Groningen, The Netherlands
Eric Vivier, Aix-Marseille University; Innate Pharma, France




Organizing Committee

Laura Airas
Maija Hollmén
Reko Leino
Olli Pentikäinen
Jessica Rosenholm
Jukka Westermarck (chair)




If you have any questions regarding the event, please contact biocityturku@bioscience.fi